📚 A 2022 Kidney International Supplement @theisn.org - www.kisupplements.org/article/S215... shows rising CKD rates and gaps in diagnosis and treatment. More precise, pathway-focused therapies are needed. 🔬 archbiopartners.com/our-science/ckd-platform/ #CKD #KidneyCare #NephSky

📚 @thelancet.com study - www.thelancet.com/journals/lan... - confirms CKD has entered the top 10 causes of death worldwide. Arch is advancing IL-32–targeting drug candidates to address chronic kidney disease at the source. 🔬 archbiopartners.com/our-science/ckd-platform #CKD #KidneyCare #NephSky

🧪 A Life Sciences review (www.sciencedirect.com/science/arti...) confirms that inflammation, vascular injury, and mitochondrial damage drive S-AKI. These same mechanisms are also active in cardiac surgery-associated AKI (CS-AKI). 🔬 archbiopartners.com/our‑science/lsaltpeptide#AKIK#CSAKIK#NephSkyky

📈 A 2025 study in NDT (doi.org/10.1093/ndt/gfaf084) found high kidney failure & mortality rates in IgA nephropathy. Arch’s CKD platform targets IL-32, a cytokine linked to kidney inflammation, complementing its AKI platform. 🔬 archbiopartners.com/our-science/ckd-platform/ #CKD #KidneyCare #NephSky

📚 An AKI case in @cureusmedical.bsky.social (doi.org/10.7759/cureus.88144) shows how difficult diagnosis can be without clear criteria. Arch’s ongoing Phase II trial for CS-AKI uses KDIGO to guide consistent diagnosis. 🔬 archbiopartners.com/our-science/lsaltpeptide #AKI #CSAKI #KDIGO #NephSky

🧬 Frontiers in Nephrology (doi.org/10.3389/fneph.2024.1436896) examines chemotherapy-related AKI. Arch is supporting an ongoing Phase II trial of cilastatin to prevent drug-induced AKI. 🔬 archbiopartners.com/our-science/cilastatin #AKI #Cilastatin #NephSky #KidneyCare @frontiersin.bsky.social

🚨 Arch Biopartners has announced that the @fraserhealth.ca Research Ethics Board has approved Royal Columbian Hospital to join its Phase II trial of LSALT peptide to prevent CS-AKI. 📖 Latest News at www.archbiopartners.com/investor-hub/ #AKI #CSAKI #KidneyCare #NephSky

🧬 @springernature.com - nature.com/articles/s41598-025-18475-z finds DPEP1 blocks NK-cell killing in colon cancer. LSALT peptide is a DPEP1 inhibitor in a Phase II trial targeting CS-AKI. Approval would validate DPEP1 and open oncology exploration. archbiopartners.com/our-science #NephSky #DPEP1

🚨 Novo Nordisk to acquire Akero Therapeutics in a $5.2B deal, expanding its MASH & metabolic portfolio with a Phase 3 FGF21 analogue @barrons.com: bit.ly/akero-novo-nordisk Arch develops on-target drugs for AKI & CKD, a condition tied to metabolic dysfunction. 🔬 archbiopartners.com/about-us #Biotech

🚨 Omeros jumps 154% after Novo Nordisk signs a $2.1B deal for Zaltenibart, now in testing for PNH and related kidney disorders. @ibdinvestors.bsky.social: bit.ly/omeros-novo-... Arch Biopartners is developing on-target drugs for AKI and CKD. 🔬 archbiopartners.com/about-us #Biotech #CKD #NephSky

A 2023 review (www.seminarsinnephrology.org/article/S027... shows how cisplatin causes AKI through inflammation, oxidative stress, and cell injury. Learn more about the Phase II trial evaluating cilastatin to protect kidneys. 🔬 archbiopartners.com/our-science/cilastatin #AKI #Cilastatin #NephSky

📉 Kidney Medicine @kidneymed.bsky.social (Dec 2024): Cilastatin was linked to a 74% lower AKI risk in clinical trials, 46% in observational studies. Overall: 48%. Arch is supporting the PONTiAK Phase II trial, now recruiting. 🔬 archbiopartners.com/our-science/cilastatin #Cilastatin #AKI #NephSky

📚 @frontiersin.bsky.social 2025 (doi.org/10.3389/fendo.2025.1513008): CKD mortality due to diabetes has nearly tripled since 1990 and is projected to continue rising. Highlights need for on-target CKD treatments. 🔬 archbiopartners.com/our-science/ckd-platform #CKD #KidneyCare #Nephsky

🌍 @sciam.bsky.social (bit.ly/sci-american...) highlights the global CKD burden and the need for better detection. Heat stress is one factor under study. Arch Biopartners has launched a CKD platform, complementing two Phase II AKI trials. 🔬 archbiopartners.com/our-science #CKD #AKI #NephSky

📚 Lancet Reg Health – Americas (www.thelancet.com/journals/lan... CKD affects 27% of people with type 1 diabetes in a U.S. cohort; >10% face severe disease. Highlights urgent need for precise CKD therapies. 🔬 archbiopartners.com/our-science/ckd-platform #ArchBiopartners #CKD #NephSky

📚 CDC, 2023 (cdc.gov/kidney-disease/php/data-research/): Over 35 million U.S. adults (more than 1 in 7) have CKD. The data highlights the epidemic scale of the disease and need for on-target CKD treatments. 🔬New CKD platform: archbiopartners.com/our-science/ckd-platform/ #CKD #KidneyCare #NephSky

🚨 Fierce Biotech: “Sparrow flies with $95M for midstage diabetes asset” (fiercebiotech.com/biotech/sparrow-flits-forward-95m-series-b-midstage-diabetes-asset). Arch Biopartners is a therapeutic biotech with 2 Phase II AKI programs and preclinical IP in CKD. 🔬 archbiopartners.com/our-science/

📚 @frontiersin.bsky.social Cardiovasc. Med. (doi.org/10.3389/fcvm.2023.1108538) - 1 in 5 adults with CS-AKI develop CKD within 90 days. Arch is a therapeutic biotech company supporting two Phase II AKI trials and a CKD platform. 🔬 archbiopartners.com/our-science #CKD #CSAKI #LSALTpeptide #NephSky

📚 Nature Reviews: Nephrology (doi.org/10.1038/s41581-024-00820-6): CKD affects more than 800M people globally, steep increase for 2030. Arch is a kidney therapeutics company with a CKD platform and two ongoing Phase II AKI trials. 🔬 archbiopartners.com/our-science/ckd-platform/ #CKD #AKI #NephSky

🚨 Fierce: “Sanofi juices up biotech investment arm with $625M” (bit.ly/sanofi-625m-cash-infusion). Arch is a therapeutic biotech with two Phase II programs for AKI and preclinical IP advancing kidney therapeutics in CKD. 🔬 archbiopartners.com/our-science/ #AKI #CKD #BiotechNews #NephSky

🧬 2024 @springernature.com Scientific Reports study (nature.com/articles/s41598-024-67020-x) found DI-AKI from anticancer drugs has a ~23.6% fatality rate, rising sharply after 2010. Cilastatin is in a Phase II trial for DI-AKI. 🔬 archbiopartners.com/our-science/cilastatin #AKI #Cilastatin #NephSky

📚 National Geographic reports a 90% rise in CKD since 1990 (nationalgeographic.com/health/article/chronic-kidney-disease-rise). Arch has announced a CKD platform targeting diabetic CKD, complementing two ongoing Phase II AKI trials. 🔬 archbiopartners.com/our-science #CKD #NephSky #KidneyCare

🚨 Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD). 🔬 Full News Release: archbiopartners.com/investor-hub/press-releases/ #KidneyCare #CKD #NephSky #ArchBiopartners

📚 A 2025 review confirms KDIGO 2012 as the leading AKI guideline (doi.org/10.3389/fmed.2025.1567359). Arch Biopartners’ Phase II trial for CS‑AKI uses KDIGO to define AKI after cardiac surgery. 🔬 archbiopartners.com/our-science/metablok #AKI #CSAKI #NephSky #ArchScience #LSALTpeptide

📊 A 2022 study in Kidney International (doi.org/10.1016/j.kint.2022.02.033) showed consistent AKI incidence and outcomes across Canada, Denmark, and the UK using harmonized KDIGO definitions. Supports the need for targeted kidney therapies. 🔬 archbiopartners.com/our-science #AKI #CSAKI #NephSky

📊 A 2025 study in Critical Care @springernature.com (doi.org/10.1186/s13054-025-05351-5) shows nearly half of ICU patients with sepsis develop AKI. Arch is supporting two Phase II trials focused on CS-AKI and DI-AKI. 🔬 archbiopartners.com/our-science #AKI #KidneyCare #NephSky #ArchBiopartners

A 2024 Frontiers review (doi.org/10.3389/fimmu.2024.1353339) shows how cancer immunotherapies can trigger acute kidney injury (AKI). Part of a 2025 research topic highlighting AKI and the urgent need for kidney protection. 🔬 archbiopartners.com/our-science #AKI #KidneyCare #ArchScience #NephSky

Frontiers cohort study (doi.org/10.3389/fmed.2024.1459170), part of a research topic, maps hospital drug classes linked to drug-induced acute kidney injury (DI-AKI). PONTIAK Phase II trial of cilastatin to prevent DI-AKI now recruiting. 🔬 archbiopartners.com/cilastatin #AKI #Cilastatin #NephSky

March 2025 Frontiers in Medicine case series (doi.org/10.3389/fmed.2025.1495705), part of a research topic, reports dialysis rescue after methotrexate-induced AKI. Arch is supporting a Phase II trial of cilastatin for kidney protection. 🔬 archbiopartners.com/cilastatin #AKI #Cilastatin #KidneyCare

2025 Frontiers in Medicine editorial (see below) on drug-induced AKI, linked to ~26% of hospital cases. Arch is supporting the development of Cilastatin in the Phase II PONTIAK trial, now recruiting. 🔬 archbiopartners.com/cilastatin Editorial www.frontiersin.org/journals/med... #KidneyCare #AKI

🧪 A 2006 Kidney Int. study showed urinary IL-18 rises early in AKI after cardiac surgery. This helped shape AKI risk models. Arch is now sponsoring a Phase II CS-AKI trial with LSALT peptide. 🔬 archbiopartners.com/our-science #AKI #CSAKI Full article: www.kidney-international.org/article/S008...

🔬A 20-year study in the Journal of Nephrology highlights the burden of AKI in critical care. Arch is supporting two Phase II trials targeting CS-AKI and DI-AKI. Arch’s clinical programs (archbiopartners.com/our-science) #AKI #TrialRationale #ArchScience Full – doi.org/10.1007/s40620-024-02189-y

🔍 A 2022 JASN consensus (doi.org/10.1681/asn.2021121605) calls for AKI trials focused on clear subtypes like CS-AKI, with better biomarkers and endpoints. Arch is supporting two Phase II trials for CS-AKI and DI-AKI. 🔬 archbiopartners.com/our-science #AKI #CSAKI #TrialRationale #ArchBiopartners

📈 Investment Executive - "Canadians missing out..." (link below). Arch is supporting two Phase II trials to prevent acute kidney injury. 📊 archbiopartners.com/about-us IE article: investmentexecutive.com/news/research-and-markets/canadians-missing-out-on-domestic-late-stage-life-sciences-firms/

Arch Biopartners’ CS-AKI Phase II clinical trial is now active at Toronto General Hospital, ranked Canada's #1 and #3 globally. First patient dosed in the trial at this leading cardiac research hospital. 🔗 dub.sh/first-patien... #ArchBiopartners #CSAKI #AKI #LSALTpeptide #clinicaltrials #ArchNews

🚨 Arch Biopartners now has two lead drug candidates in active Phase II trials: 🔹 Cilastatin: in the PONTIAK trial for drug-toxin-related AKI, now open for recruitment 🔹 LSALT peptide: cardiac surgery-associated AKI 🔗 archbiopartners.com/investor-hub... #AKI #Cilastatin #LSALTpeptide #ArchNews

🔬 2017 review in Anesth Analg (doi.org/10.1213/ane.0000000000002369) noted perioperative AKI as common but overlooked, underscoring the need for solutions. Arch’s LSALT peptide is in Phase II to address this risk. 🌐 More: archbiopartners.com/our-science #CSAKI #AKI #KidneyCare #ArchBiopartners

📊 Even mild post-surgical AKI raises mortality, ICU time, and costs (NDT, 2008, academic.oup.com/ndt/article-...). 🔗 Arch is targeting CS-AKI in an ongoing, sponsor-led international Phase II trial: archbiopartners.com/our-science/metablok/#trial-history #AKI #CSAKI #KidneyCare #LSALTpeptide

💊 2024 study in “Frontiers in Medicine” (doi.org/10.3389/fmed.2024.1459170): in a series about drug-induced AKI (DI-AKI), found the problem remains a top cause of hospital AKI. Arch is advancing cilastatin to help prevent this risk. 🔬 archbiopartners.com/cilastatin #Cilastatin #AKI #KidneyCare

Friday Deep Dive — 2009 study in “Circulation” (doi.org/10.1161/CIRCULATIONAHA.108.800011) found cardiac surgery–associated AKI predicts higher long-term mortality, even years after discharge. 🔬 International CS-AKI Phase II Trial: archbiopartners.com/our-science #CSAKI #KidneyCare #ArchScience

💰 2022 study in J Crit Care (doi.org/10.1016/j.jcrc.2021.12.011) found delayed RRT in CS-AKI = longer ICU stays and higher costs. Arch’s science program is focused on preventing CS-AKI and improving patient outcomes. 🔬 archbiopartners.com/our-science/ #CSAKI #ArchScience #AKI #KidneyCare

📚 2024 review in Kidney360 (doi.org/10.34067/KID.0000000000000466) emphasizes the burden of CS-AKI, with inflammation and ischemia as central causes—and no approved treatments available. 🔬 Arch is focused on prevention: archbiopartners.com/our-science/ #CSAKI #AKI #KidneyCare #ArchScience

🫀 A 2018 international consensus led by ADQI (doi.org/10.1161/JAHA.118.008834) cites inflammation, IRI, and toxins as causes of AKI. These drivers match the targets of Arch Biopartners’ clinical strategy. 📖 Learn more: archbiopartners.com/our-science #CSAKI #AKI #TrialRationale #KidneyCare

🌐 Cardiac surgery demand exceeds global capacity 12-to-1 (June 2024 - doi.org/10.1016/j.atssr.2023.11.019). As access grows, so does the burden of CS-AKI—and the need for prevention. 📖 Learn more: archbiopartners.com/our-science #ArchBiopartners #CSAKI #TrialRationale #ArchScience #InvestorFAQ

📘 2024 BMJ Open study (doi.org/10.1136/bmjopen-2023-076142) co-authored by Arch scientists confirmed LSALT was safe in COVID-19 patients and validated DPEP1 as a therapeutic target—key findings for the CS-AKI trial. 📖 archbiopartners.com/our-science/our-publications/ #LSALTpeptide #DPEP1 #KidneyCare

📊 AKI affects up to 40% of patients following cardiac surgery, as noted in a key 2011 review in Ann Thorac Surg (doi.org/10.1016/j.athoracsur.2011.04.123). Arch’s clinical trials focus on preventing AKI before it starts. 🔬 Learn more archbiopartners.com/our-science/ #ArchBiopartners #AKI #KidneyCare

📈 A CDC-backed study in MMWR (doi.org/10.15585/mmwr.mm6710a2) found AKI-related hospitalizations in the U.S. increased 4x from 2000 to 2014. This sharp rise highlights AKI as an urgent unmet need in clinical care. 🔬 Phase II AKI trials - archbiopartners.com/our-science/ #AKI #KidneyCare #ArchScience

💊 2023 Kidney Int. Reports study (doi.org/10.1016/j.ekir.2023.07.037) finds drug-induced AKI (DI-AKI) patients are more likely to develop Stage 3 AKI and kidney disease at discharge. Arch is developing cilastatin to help prevent DI-AKI - archbiopartners.com/cilastatin #AKI #Cilastatin #KidneyCare

🩺 A 2025 JAMA Network Open study (doi.org/10.1001/jamanetworkopen.2025.8342) finds CS-AKI rates vary widely—11.7% to 32.8%—driven by intraoperative practices. 🔔 How Arch is addressing AKI in cardiac surgery: archbiopartners.com/our-science #CSAKI #AKI #ArchScience #TrialRationale #KidneyCare

🧬 Weekly series for new followers—2019 Cell paper (doi.org/10.1016/j.cell.2019.07.017), co-authored by Arch scientists, identified DPEP1 as a driver of neutrophil inflammation in the kidneys, liver, and lungs. 📖 Arch Publications: dub.sh/cell-dpep1-2019 #DPEP1 #ArchScience #LSALTpeptide #KidneyCare